Myriad Genetics Inc
MYGN3.890USD
-0.140-3.47%
Handelsschluss 05/09, 16:00（ET）Kurse um 15 Minuten verzögert
358.66MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Myriad Genetics Inc Unternehmen
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.
Unternehmensinformationen
Unternehmens-codeMYGN
Name des UnternehmensMyriad Genetics Inc
IPO-datumOct 06, 1995
Gegründet am1992
CEOMr. Samraat S. (Sam) Raha
Anzahl der mitarbeiter2700
WertpapierartOrdinary Share
GeschäftsjahresendeOct 06
Addresse322 North 2200 West
StadtSALT LAKE CITY
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl84116
Telefon18015843600
Websitehttps://myriad.com/
Unternehmens-codeMYGN
IPO-datumOct 06, 1995
Gegründet am1992
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Brian Donnelly
Mr. Brian Donnelly
Chief Commercial Officer
Chief Commercial Officer
397.53K
--
Mr. Mark S. Verratti
Mr. Mark S. Verratti
Chief Operating Officer and Chief Commercial Officer
Chief Operating Officer and Chief Commercial Officer
221.65K
-11.52%
Ms. Margaret (Maggie) Ancona
Ms. Margaret (Maggie) Ancona
Senior Vice President, Chief of Staff
Senior Vice President, Chief of Staff
128.68K
+56.61%
Ms. Shereen Solaiman
Ms. Shereen Solaiman
Chief People Officer
Chief People Officer
110.96K
+98.89%
Dr. Lee Nisley Newcomer, M.D.
Dr. Lee Nisley Newcomer, M.D.
Independent Director
Independent Director
82.34K
--
Ms. Rashmi Kumar
Ms. Rashmi Kumar
Independent Director
Independent Director
77.39K
--
Dr. Dale Muzzey
Dr. Dale Muzzey
Chief Scientific Officer
Chief Scientific Officer
45.88K
-46.96%
Ms. S. Louise Phanstiel, CPA
Ms. S. Louise Phanstiel, CPA
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Matt Scalo
Mr. Matt Scalo
Investor Relations
Investor Relations
--
--
Ms. Jennifer Fox
Ms. Jennifer Fox
Chief Legal Officer
Chief Legal Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Brian Donnelly
Mr. Brian Donnelly
Chief Commercial Officer
Chief Commercial Officer
397.53K
--
Mr. Mark S. Verratti
Mr. Mark S. Verratti
Chief Operating Officer and Chief Commercial Officer
Chief Operating Officer and Chief Commercial Officer
221.65K
-11.52%
Ms. Margaret (Maggie) Ancona
Ms. Margaret (Maggie) Ancona
Senior Vice President, Chief of Staff
Senior Vice President, Chief of Staff
128.68K
+56.61%
Ms. Shereen Solaiman
Ms. Shereen Solaiman
Chief People Officer
Chief People Officer
110.96K
+98.89%
Dr. Lee Nisley Newcomer, M.D.
Dr. Lee Nisley Newcomer, M.D.
Independent Director
Independent Director
82.34K
--
Ms. Rashmi Kumar
Ms. Rashmi Kumar
Independent Director
Independent Director
77.39K
--
Umsatzaufteilung
Währung: USDUpdate-Zeit: Sun, Apr 6
Währung: USDUpdate-Zeit: Sun, Apr 6
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Hereditary Cancer
364.50M
43.52%
Prenatal
177.10M
21.14%
Pharmacogenomics
170.20M
20.32%
Tumor Profiling
125.80M
15.02%
Nach RegionUSD
Name
Umsatz
Anteil
United States
769.50M
91.87%
Rest of world
68.10M
8.13%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Hereditary Cancer
364.50M
43.52%
Prenatal
177.10M
21.14%
Pharmacogenomics
170.20M
20.32%
Tumor Profiling
125.80M
15.02%
Aktionäre
Update-Zeit: Sun, May 4
Update-Zeit: Sun, May 4
Aktionärsstatistik
Art
Aktionärsstatistik
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
15.02%
The Vanguard Group, Inc.
11.52%
Wellington Management Company, LLP
6.51%
State Street Global Advisors (US)
5.99%
Millennium Management LLC
4.71%
Other
56.24%
Aktionärsstatistik
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
15.02%
The Vanguard Group, Inc.
11.52%
Wellington Management Company, LLP
6.51%
State Street Global Advisors (US)
5.99%
Millennium Management LLC
4.71%
Other
56.24%
Art
Aktionäre
Anteil
Investment Advisor/Hedge Fund
43.56%
Investment Advisor
34.86%
Hedge Fund
18.62%
Individual Investor
2.85%
Research Firm
2.64%
Pension Fund
1.14%
Bank and Trust
0.40%
Sovereign Wealth Fund
0.10%
Insurance Company
0.04%
Institutionelle Beteiligung
Update-Zeit: Tue, Mar 4
Update-Zeit: Tue, Mar 4
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q1
510
96.13M
104.30%
-2.66M
2024Q4
516
96.89M
106.12%
-1.41M
2024Q3
505
95.02M
104.61%
-5.50M
2024Q2
486
96.79M
106.52%
-6.22M
2024Q1
460
98.19M
108.68%
+613.48K
2023Q4
464
93.46M
105.77%
+2.70M
2023Q3
471
86.01M
104.78%
-3.73M
2023Q2
480
84.60M
103.32%
-6.34M
2023Q1
483
85.87M
105.37%
-2.69M
2022Q4
490
83.72M
103.14%
-4.93M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
BlackRock Institutional Trust Company, N.A.
14.32M
15.68%
+446.35K
+3.22%
Dec 31, 2024
The Vanguard Group, Inc.
10.57M
11.58%
+279.38K
+2.71%
Dec 31, 2024
Wellington Management Company, LLP
6.00M
6.58%
-711.99K
-10.60%
Dec 31, 2024
State Street Global Advisors (US)
5.53M
6.05%
+822.26K
+17.48%
Dec 31, 2024
Millennium Management LLC
4.35M
4.76%
-831.32K
-16.06%
Dec 31, 2024
Glenview Capital Management, LLC
4.16M
4.55%
+2.90M
+229.55%
Dec 31, 2024
EARNEST Partners, LLC
3.97M
4.35%
+15.65K
+0.40%
Dec 31, 2024
Camber Capital Management LP
3.10M
3.4%
-850.00K
-21.52%
Dec 31, 2024
Artisan Partners Limited Partnership
2.77M
3.03%
+336.77K
+13.86%
Dec 31, 2024
Disciplined Growth Investors, Inc.
2.56M
2.8%
+29.14K
+1.15%
Dec 31, 2024
Mehr Anzeigen
Verbundene ETFs
Update-Zeit: Tue, May 6
Update-Zeit: Tue, May 6
Name
Anteil
Invesco Biotechnology & Genome ETF
1.95%
Global X Genomics & Biotechnology ETF
1.64%
WisdomTree BioRevolution Fund
0.64%
Invesco S&P SmallCap Health Care ETF
0.46%
First Trust Nasdaq Lux Digi Health Solutions ETF
0.31%
SPDR S&P Biotech ETF
0.27%
Strategas Global Policy Opportunities ETF
0.18%
Direxion Daily S&P Biotech Bull 3X Shares
0.17%
Inspire Small/Mid Cap ESG ETF
0.14%
SPDR S&P 600 Small Cap Value ETF
0.12%
Mehr Anzeigen
Invesco Biotechnology & Genome ETF
Anteil1.95%
Global X Genomics & Biotechnology ETF
Anteil1.64%
WisdomTree BioRevolution Fund
Anteil0.64%
Invesco S&P SmallCap Health Care ETF
Anteil0.46%
First Trust Nasdaq Lux Digi Health Solutions ETF
Anteil0.31%
SPDR S&P Biotech ETF
Anteil0.27%
Strategas Global Policy Opportunities ETF
Anteil0.18%
Direxion Daily S&P Biotech Bull 3X Shares
Anteil0.17%
Inspire Small/Mid Cap ESG ETF
Anteil0.14%
SPDR S&P 600 Small Cap Value ETF
Anteil0.12%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten